BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Solvay SA : Operating Result In The Fourth Quarter (EUR 313 Million) Clearly Improved Compared To Last Year (EUR 125 Million) In Every Sector Of Activity; For The Year Overall, The Decrease Was Limited To 6%


2/18/2010 11:39:44 AM

BRUSSELS, BELGIUM--(Marketwire - February 18, 2010) -


REGULATED INFORMATION

Operating result in the fourth quarter (EUR 313 million) clearly improved compared to last year (EUR 125 million) in every sector of activity; for the year overall, the decrease was limited to 6%

- Sales (EUR 8,485 million) down 11% compared to 2008 (-3% in the fourth quarter)

- Operating result (EUR 905 million) down by 6% for the year overall:

. Pharmaceuticals (EUR 649 million) presented as "Discontinued Operations": record result thanks to sustained growth for main products and cost reduction in the fourth quarter

. Chemicals (EUR 246 million): up by 3% due to drop in fixed costs and energy costs, and despite a significant decline in demand

. Plastics (EUR 73 million): down compared to 2008, with the economic crisis particularly affecting the markets in this Sector (construction, automotive, electronics, equipment parts); strong cost reduction in each activity; in the fourth quarter, confirmation of improved demand in Specialty Polymers

- Net income of Group (EUR 553 million) up by 23% compared to 2008 (impacted by Fortis)

- Dividend proposed: 2.9333 EUR gross (2.20 EUR net) per share (stable compared to 2008)

Group sales (EUR 8,485 million) are down by 11% compared to last year. The development by sector was contrasted: Pharmaceuticals: +3%, Chemicals: - 12%, Plastics: -19%. The primary markets of the Chemicals and Plastics Sectors were hard hit by the economic crisis. Since mid-2009, however, there has been some improvement in demand in most of the markets; this improvement remains fragile, however. It is more apparent in Asia than in the rest of the world, in particular in comparison to Europe. Sales in the fourth quarter dropped by 3% compared to the same period in 2008 and amounted to EUR 2,199 million.

Group operating result (REBIT (1); EUR 905 million) was down by 6% compared to 2008. In the fourth quarter (EUR 313 million), there was improvement both compared to the preceding quarter (EUR 285 million) and compared to the fourth quarter of 2008 (EUR 125 million). Operating result for the Pharmaceuticals Sector in 2009 reached the record level of EUR 649 million, up by 27% compared to last year, in line with the objectives of the Inspire project. In the fourth quarter (EUR 238 million), it improved significantly (+73%), especially due to a drop in costs and discontinuation of depreciation since the Sector is being booked as "Discontinued Operations." Operating result for the Chemicals Sector (EUR 246 million in 2009, including EUR 68 million in the fourth quarter) was up by 3%, in particular due to the drop in fixed costs and energy costs and despite a significant decline in demand. In Plastics, there is a net decline (EUR 73

million in 2009 compared to EUR 264 million in 2008) due to the significant impact of the crisis on the primary markets of this Sector. This impact, however, was mitigated by a significant cost-reduction and cash optimization program implemented throughout the Sector. In the fourth quarter, there was a positive result of EUR 27 million while the same period in 2008 showed a loss.

Strict costs control and continued structural changes (adaptation of production and reduction in headcount) mitigated the impact on results in a very difficult economic context. At constant scope and EUR/USD exchange rate, the Group reduced fixed production costs and commercial and administrative costs for about EUR 105 million in the Chemicals, Plastics and "Corporate and Business Support" Sectors and for about EUR 120 million in the Pharmaceuticals Sector, compared to 2008. Headcount continued to decrease (at constant perimeter: about 1,630 persons for the entire year).

In total, the Group's operating margin (REBIT on sales) was 10.7% in 2009 compared to 10.2% in 2008.

The net income of the Group (EUR 553 million) improved by 23% compared to 2008. It should be recalled that the net result from last year had been impacted in an amount up to EUR 309 million by an extraordinary write-down of holdings in Fortis.

REBITDA (2) was EUR 1,375 million, down by 4% compared to 2008; it improved by 64% in the fourth quarter (EUR 413 million). In the context of the crisis, priority was given throughout the year to generation of cash and maintenance of a sound financial situation. Aside from cost-reduction measures, this priority generated a significant

decrease in working capital needs (decline in industrial working capital of more than 9%, or a decrease of EUR 145 million) and investment expenditures (down by 57%, or a decrease of EUR 753 million) compared to 2008. The net debt to equity ratio reached 26% at the end of 2009 compared to 34% at the end of 2008. It should be noted

that the first significant maturity for debt reimbursement will not occur until 2014.

The Board of Directors agreed on February 17, 2010 to propose to the General Shareholders Meeting of May 11, 2010 the payment of a gross dividend of 2.9333 EUR (2.20 EUR net) per share, stable compared to 2008.

The Solvay Group announced at the end of September 2009 its decision to refocus its activities and to sell its entire pharmaceutical business in order to accelerate its strategy of profitable and sustainable growth. This transaction closed on February 15 2010. The after taxes capital gain on the transaction is estimated at EUR 1.7 billion on January 1st, 2010. It will be booked in the consolidated accounts of the 1st quarter 2010 in the "discontinued operations". This capital gain is subject to limited adjustment for the variations in net asset value of the pharmaceuticals activities from January 1st, 2010 to February 15 2010.

Furthermore, provisions to adapt the organization of the Group will have to be created in 2010. These amounts are not determined at this stage and will be part of subsequent communication.

Sales and operating result for the Pharmaceuticals Sector reached record levels in 2009. Sales (EUR 2,791 million) were up by 3% compared to 2008 (+3% at constant exchange rates). They were down by 1% in the fourth quarter (+4% at constant exchange rates). The sales benefited from the sustained growth of certain drugs such as Androgel®, Creon® and Influvac®. On the other hand, it was negatively impacted by significant pressure from generic competition and by the halt of distribution of ESTRATEST®, decided upon in March 2009. Sales in emerging markets continued to improve, despite the negative effects of exchange rates. Emerging markets represented about 20% of sales in the Pharmaceuticals Sector in 2009. Overall for the year, operating result reached a record level of EUR 649 million (+27% compared to 2008). During the fourth quarter (EUR 238 million), it benefited from a significant reduction of costs and the discontinuation of depreciation since the Sector is being booked as "Discontinued Operations" (positive impact of EUR 28 million). It should be noted that there was the capital gain of EUR 17 million on the sale of a non-strategic product (Flammazine®) as well as the reversal of a bad debt reserve of 10 MEUR.

Chemicals Sector sales (EUR 2,713 million) decreased by 12% following a decline in demand compared to 2008. Slight improvement in sales volume was observed in the second half compared to the first half of the year. In the fourth quarter, pressure on the sales prices of hydrogen peroxide and soda ash remained strong; it should be noted, however, that the specialty soda ash derivatives show a favorable trend. The price of caustic soda has gained slightly after its sharp drop in the second and third quarters. Operating result for 2009 (EUR 246 million) was 3% higher than 2008 (EUR 238 million) due to the reduction of fixed costs and energy costs. In the fourth quarter (EUR 68 million), it improved significantly compared to last year (EUR 31 million). Strict costs control at all levels and the significant drop in energy costs in fact mitigated the impact on the result of the drop in volumes and of the downward trend of certain sales prices observed since mid-2009.

Plastics Sector sales (EUR 2,982 million) decreased by 19% compared to 2008. The crisis had a significant impact on the primary markets of the Sector, especially automotive, construction, electronics and electricity as well as equipment parts. It should be noted that since the start of the second half of 2009, there was improved demand in several markets covered by Specialty Polymers. This improvement is, however, less noticeable in the construction sector in Europe and in the United States, an important market for Vinyls. This evolution explains the significant improvement of the operating result in the Specialties cluster in the 4th quarter compared to the preceding quarters and a low operating result for the Vinyls cluster, impacted as well by the slowdown in activity toward the end of the year and by the low level of PVC margins in Europe and South America. Operating result for the Sector for the full year (EUR 73 million) remained much lower than last year (EUR 264 million). Significant efforts undertaken by the Sector in terms of cash generation and cost reduction at all levels ensured nonetheless strong resistance to an especially difficult economic environment.

In 2010, the focus will go to the optimal reinvestment after the disposal of the pharmaceutical activities. Thanks to its growth initiatives, its competitive positions and the measures taken in the last two years, Solvay is prepared in case of a longer crisis. Market conditions remain challenging.

SOLVAY Group - Summary Financial Information

+------------------------+---------+---------+----------+--------+--------+
|Million EUR             |  2008   |  2009   |  2009/   |  4th   |  4th   |
+------------------------+---------+---------+----------+--------+--------+
|(except for per-share   |Total (3)|Total (4)|      2008|quarter |quarter |
|figures in EUR)         |         |         |          |        |        |
+------------------------+---------+---------+----------+--------+--------+
|                        |         |         |          |   2008 |   2009 |
+------------------------+---------+---------+----------+--------+--------+
|                        |         |         |% on total| Total4 | Total4 |
+------------------------+---------+---------+----------+--------+--------+
|Sales                   |    9,490|    8,485|      -11%|  2,273 |  2,199 |
+------------------------+---------+---------+----------+--------+--------+
|REBIT                   |      965|      905|       -6%|    125 |    313 |
+------------------------+---------+---------+----------+--------+--------+
|REBIT/Sales             |   10.20%|   10.70%|        ns|  5.50% | 14.20% |
+------------------------+---------+---------+----------+--------+--------+
|Non-recurring items     |       20|     -105|        ns|    -31 |    -41 |
+------------------------+---------+---------+----------+--------+--------+
|EBIT (4)                |      985|      800|      -19%|     94 |    272 |
+------------------------+---------+---------+----------+--------+--------+
|Charges on net          |      -93|     -151|       62%|    -29 |    -34 |
|indebtedness            |         |         |          |        |        |
+------------------------+---------+---------+----------+--------+--------+
|Income from investments |     -299|       -5|        ns|    -53 |     -2 |
+------------------------+---------+---------+----------+--------+--------+
|Earnings before taxes   |      592|      643|        9%|     12 |    237 |
+------------------------+---------+---------+----------+--------+--------+
|Income taxes            |     -143|      -90|      -37%|     11 |    -38 |
+------------------------+---------+---------+----------+--------+--------+
|Net income of the Group |      449|      553|       23%|     23 |    199 |
+------------------------+---------+---------+----------+--------+--------+
|Net income (Solvay      |         |         |          |        |        |
|share)                  |      405|      516|       27%|     29 |    188 |
+------------------------+---------+---------+----------+--------+--------+
|Total depreciation      |      417|      496|       19%|    139 |    101 |
+------------------------+---------+---------+----------+--------+--------+
|REBITDA                 |    1,436|    1,375|       -4%|    252 |    413 |
+------------------------+---------+---------+----------+--------+--------+
|Cash flow               |      866|    1,049|       21%|    162 |    300 |
+------------------------+---------+---------+----------+--------+--------+
|Results per share (5)   |     4.92|     6.28|       28%|   0.35 |   2.28 |
+------------------------+---------+---------+----------+--------+--------+
|Net debt to equity ratio|      34%|      26%|          |        |        |
+------------------------+---------+---------+----------+--------+--------+

+-------------------------+------------------+
|Million EUR              |4th quarter 2009/ |
+-------------------------+------------------+
|(except for per-share    | 4th quarter 2008 |
|figures in EUR)          |                  |
+-------------------------+------------------+
|                         |                  |
+-------------------------+------------------+
|                         |       % on total |
+-------------------------+------------------+
|Sales                    |              -3% |
+-------------------------+------------------+
|REBIT                    |             150% |
+-------------------------+------------------+
|REBIT/Sales              |               ns |
+-------------------------+------------------+
|Non-recurring items      |               ns |
+-------------------------+------------------+
|EBIT (4)                 |             188% |
+-------------------------+------------------+
|Charges on net           |              15% |
|indebtedness             |                  |
+-------------------------+------------------+
|Income from investments  |               ns |
+-------------------------+------------------+
|Earnings before taxes    |               ns |
+-------------------------+------------------+
|Income taxes             |               ns |
+-------------------------+------------------+
|Net income of the Group  |               ns |
+-------------------------+------------------+
|Net income (Solvay share)|               ns |
+-------------------------+------------------+
|Total depreciation       |             -27% |
+-------------------------+------------------+
|REBITDA                  |              64% |
+-------------------------+------------------+
|Cash flow                |              85% |
+-------------------------+------------------+
|Results per share (5)    |                  |
+-------------------------+------------------+
|Net debt to equity ratio |                  |
+-------------------------+------------------+

Notes on Solvay Group summary financial information

Non-recurring items amounted to EUR -105 million in 2009 (EUR -41 million in the fourth quarter). They included asset write-downs of EUR 17 million in the Organics cluster (Chemicals Sector) and EUR 12 million in the Pharmaceuticals Sector, various charges for restructuring (mothballing of the hydrogen peroxide unit at Bitterfeld, shutdown of the precipitated calcium carbonate production unit at Angera), as well as the increase by EUR 25 million of the reserve created in the context of contract litigation.


Charges on net indebtedness amounted to EUR -151 million at the end of December 2009 (of which EUR -135 million were charges on borrowing). They were affected by financing charges in local currencies on our development in eastern countries, especially in Russia and in Bulgaria (EUR -17 million), and by the low yield in cash (1.0%). Financial debt is covered at 82% at an average fixed rate of 5.1% with a duration of 6.2 years; the first significant maturity for debt reimbursement will not occur until 2014. In May 2009, the Group issued a 6-year bond in the amount of EUR 500 million at 5%. This issue permitted consolidation of its long-term financing structure, among other things by refinancing short term commercial paper.

Income taxes amounted to EUR -90 million. The effective tax rate at the end of December 2009 was 14% at Group's level due to tax credits. These tax credits are especially related to Pharmaceuticals research (EUR 37 million), which contribute to the low tax rate for discontinued operations.

The net income of the Group (EUR 553 million) improved by 23% compared to 2008. In the fourth quarter, it amounted to EUR 199 million, clearly higher than last year (EUR 23 million). It should be recalled that the net result of 2008 had been affected by the non-recurring write-down (EUR 309 million of which EUR 53 million were in the fourth quarter) of holdings in Fortis. Minority interests amounted to EUR 37 million. The net result per share amounted to 6.28 EUR (compared to 4.92 EUR at the end of December 2008).

REBITDA amounted to EUR 1,375 million, down by 4% compared to 2008. It improved by 64% in the fourth quarter (EUR 413 million). It should be noted that total depreciation (EUR 496 million) was significantly higher compared to 2008 (EUR 417 million), recalling that total depreciation of last year benefited from reversal of an impairment (EUR 92 million) on the trona mine (natural soda ash).

Equity amounted to EUR 5,160 million at the end of 2009, up by EUR 415 million compared to the end of 2008 (EUR 4,745 million).

The Group set as a major priority the maintenance of a solid financial structure, in particular in the current economic climate. Due to the significant reduction in industrial working capital (by more than 9%, or a decrease of EUR 145 million) and investment expenditures (down by 57%, or a decrease of EUR 753 million) compared to last year, the net debt decreased by EUR 264 million in 2009, to amount to EUR 1,333 million at the end of December 2009. The net debt to equity ratio amounted to 26% (compared to 34% at the end of 2008), demonstrating the importance accorded to this by the entire Group.

The Board of Directors agreed on February 17, 2010 to propose to the General Shareholders Meeting of May 11, 2010 the payment of a gross dividend of 2.9333 EUR (2.20 EUR net) per share, stable compared to 2008. Based on the closing price of February 16, 2010 (71.73 EUR), this represents a gross dividend yield of 4.1% and 3.1% net. In addition, it should be recalled that the Group's dividend policy consists of increasing it anytime possible, and avoiding, if possible, decreasing it. For 28 years, the dividend has gradually increased and has never been reduced.

RESEARCH & DEVELOPMENT AND INVESTMENTS

In the context of the economic crisis, the Solvay Group decided to significantly reduce its investments in 2009. They represented EUR 567 million, or a decrease of 57% compared to the investment amounts for 2008 (EUR 1,320 million).

In 2010, the Solvay Group will continue to manage its balance sheet with great scrutiny, since the economic context remains difficult. Aside from reinvestment of the proceeds from the sale of the Pharmaceuticals Sector, the investment budget for 2010 amounts to EUR 673 million. Just as in 2009, outside of investments related to health, safety and environmental, they will be concentrated on a very limited number of strategic projects, oriented by priority toward geographic expansion of the Group and toward choices made in terms of sustainable development.

Research and Development (R&D) expenditures reached EUR 555 million in 2009 of which EUR 416 million in the Pharmaceuticals Sector. The R&D expenditures budget for 2010 decreased down to EUR 148 million due to sale of the Pharmaceuticals activities.

RESULTS BY SEGMENT (6)

+-------------------------+------+------+-------+--------+--------+
|Million EUR              |2008  |2009  |2009 / |  4th   |  4th   |
+-------------------------+------+------+-------+--------+--------+
|                         |      |      |  2008 |quarter |quarter |
+-------------------------+------+------+-------+--------+--------+
|                         |      |      |       |   2008 |   2009 |
+-------------------------+------+------+-------+--------+--------+
|                         |9,490 |8,485 |  -11% |  2,273 |  2,199 |
+-------------------------+------+------+-------+--------+--------+
|GROUP SALES (7)          |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|Chemicals                |3,096 |2,713 |  -12% |    766 |    649 |
+-------------------------+------+------+-------+--------+--------+
|Plastics                 |3,695 |2,982 |  -19% |    753 |    802 |
+-------------------------+------+------+-------+--------+--------+
|Pharmaceuticals          |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|"Discontinued Operations"|2,699 |2,791 |    3% |    754 |    748 |
+-------------------------+------+------+-------+--------+--------+
|REBIT                    |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|                         |  965 |  905 |   -6% |    125 |    313 |
+-------------------------+------+------+-------+--------+--------+
|GROUP                    |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|Chemicals                |  238 |  246 |    3% |     31 |     68 |
+-------------------------+------+------+-------+--------+--------+
|Plastics                 |  264 |   73 |  -72% |    -26 |     27 |
+-------------------------+------+------+-------+--------+--------+
|Corporate and Business   |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|Support                  |  -46 |  -63 |   36% |    -17 |    -19 |
+-------------------------+------+------+-------+--------+--------+
|Pharmaceuticals          |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|"Discontinued Operations"|  509 |  649 |   27% |    138 |    238 |
+-------------------------+------+------+-------+--------+--------+
|REBITDA                  |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|                         |1,436 |1,375 |   -4% |    252 |    413 |
+-------------------------+------+------+-------+--------+--------+
|GROUP                    |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|Chemicals                |  398 |  413 |    4% |     73 |    110 |
+-------------------------+------+------+-------+--------+--------+
|Plastics                 |  458 |  285 |  -38% |     27 |     82 |
+-------------------------+------+------+-------+--------+--------+
|Corporate and Business   |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|Support                  |  -37 |  -54 |   47% |    -15 |    -17 |
+-------------------------+------+------+-------+--------+--------+
|Pharmaceuticals          |      |      |       |        |        |
+-------------------------+------+------+-------+--------+--------+
|"Discontinued Operations"|  617 |  731 |   18% |    167 |    238 |
+-------------------------+------+------+-------+--------+--------+
+-------------------------+------+------+-------+--------+--------+

+-------------------------+-------------------+
|Million EUR              |4th quarter 2009 / |
+-------------------------+-------------------+
|                         |  4th quarter 2008 |
+-------------------------+-------------------+
|                         |                   |
+-------------------------+-------------------+
|                         |               -3% |
+-------------------------+-------------------+
|GROUP SALES (7)          |                   |
+-------------------------+-------------------+
|Chemicals                |              -15% |
+-------------------------+-------------------+
|Plastics                 |                7% |
+-------------------------+-------------------+
|Pharmaceuticals          |                   |
+-------------------------+-------------------+
|"Discontinued Operations"|               -1% |
+-------------------------+-------------------+
|REBIT                    |                   |
+-------------------------+-------------------+
|                         |              150% |
+-------------------------+-------------------+
|GROUP                    |                   |
+-------------------------+-------------------+
|Chemicals                |              116% |
+-------------------------+-------------------+
|Plastics                 |                ns |
+-------------------------+-------------------+
|Corporate and Business   |                   |
+-------------------------+-------------------+
|Support                  |               12% |
+-------------------------+-------------------+
|Pharmaceuticals          |                   |
+-------------------------+-------------------+
|"Discontinued Operations"|               73% |
+-------------------------+-------------------+
|REBITDA                  |                   |
+-------------------------+-------------------+
|                         |               64% |
+-------------------------+-------------------+
|GROUP                    |                   |
+-------------------------+-------------------+
|Chemicals                |               51% |
+-------------------------+-------------------+
|Plastics                 |              206% |
+-------------------------+-------------------+
|Corporate and Business   |                   |
+-------------------------+-------------------+
|Support                  |               14% |
+-------------------------+-------------------+
|Pharmaceuticals          |                   |
+-------------------------+-------------------+
|"Discontinued Operations"|               42% |
+-------------------------+-------------------+
+-------------------------+-------------------+

Recent strategic developments

Strategic refocus of activities in the Solvay Group

The Board of Directors decided at the end of September 2009 to refocus the activities of the Solvay Group and to sell its entire pharmaceutical business in order to accelerate its strategy of profitable and sustainable growth.

This decision resulted from an in-depth analysis and evaluation of the different strategic options for the future development of the pharmaceuticals activities of the Group. Among the different options analyzed, the option to sell the pharmaceuticals activities was selected. It offers to all the Group's activities, pharmaceuticals and non- pharmaceuticals, the best possibilities for their future development.

The Group's pharmaceuticals activities were sold to Abbott for a total Enterprise Value of about EUR 5.2 billion. This includes a first cash payment at closing of EUR 4.5 billion and additional potential cash payments of up to EUR 300 million if specific milestones are met between 2011 and 2013. It also includes the assumption of certain liabilities and sale price adjustments, which Solvay valued at approximately EUR 360 million on January 1st, 2010.

This sale transaction closed on February 15 2010.

Solvay will reinvest the proceeds from the transaction in organic and sizeable external growth, focused on long-term value creation. This will be done by investments in high value-added activities and strategic projects in chemicals and plastics, by continuing the geographic expansion into regions with growth potential, and by pursuing the development of activities and new products with low energy footprint and which we expect will reduce the cyclicality in Solvay's portfolio of activities. Evaluations about such reinvestments are ongoing.

The proceeds of the sale of the Pharmaceuticals activities will temporarily be invested in short duration government (Germany, France, The Netherlands, Belgium) and highest rated treasury instruments and in own treasury shares of maximum 5.1 million shares (6% of the issued capital).

The Solvay Group's philosophy remains unaltered: realize sustained growth with leading positions and maintain a conservative financial structure.

Information by business segment

It was decided to introduce in the financial reporting, as of 2010, a specific segment for New Business Development (NBD) activities, in order to better highlight the research activities being carried out, outside the Strategic Business Units, in promising and important areas of development for the Group.

The NBD activity is organized into strategic platforms which combine programs linked to a common area.

A first Competence Centre, Future Businesses, has as its mission to innovate by taking measured risks to develop new assemblies of functional materials in the applications of tomorrow. It manages two platforms - Renewable Energies and Printed Organic Electronics.

The second Competence Centre, Advanced Technologies, is tasked with finding and acquiring of innovative technological know-how of potential interest to Solvay. Two platforms are currently active: Nanotechnologies and Renewable Chemistry.

More information regarding the NBD activity is available in the annual report.

(1) REBIT: measure of operating performance (this is not an IFRS concept as such)

(2) REBITDA: REBIT, before recurring depreciation and amortization

(3) Total < > = ongoing activities and "discontinued operations" as presented in the "Consolidated Income Statement " table

(4) EBIT: results before financial charges and taxes

(5) Calculated on the basis of the weighted average of the number of shares in the period, after deduction of own shares purchased to cover the stock option program, or a total of 82,317,792 shares at the end of 2008 and 82,143,247 shares at the end of 2009

(6) Results by segment include results from the three sectors of the Group, as well as Corporate and Business Support.

(7) These are sales after elimination of inter-company sales.

The full press release is available on http://www.solvay-investors.com/

ERIK DE LEYE
Corporate Press Officer
erik.deleye@solvay.com

PATRICK VERELST
patrick.verelst@solvay.com

This information is provided by HUGIN




Read at BioSpace.com

Solvay SA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->